James Rubenstein
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma (NCT05351593) | James Rubenstein | 2022-06-08 |
| Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma (NCT04656431) | James Rubenstein | 2021-06-29 |
Track James Rubenstein automatically
Every clearance here is in the API, with alerts when new ones post.